OXYCONTIN MAKER GETTING PATENT TO REFORMULATE OFTEN-ABUSED DRUG

ROANOKE, Va. -- The maker of OxyContin, a prescription painkiller linked to
a growing number of overdoses and deaths, said Thursday that it has come up
with blueprints for a "smart pill" that would be tougher to abuse.

The new painkiller, which has yet to be named and would not be available
for at least three years, would destroy its own narcotic ingredients if
crushed into a powder and snorted or injected -- the typical manner in
which OxyContin currently is abused.

"Addicts and abusers are going to find this very undesirable," said Dr. J.
David Haddox, senior medical director for Purdue Pharma LP of Stamford,
Conn. "Before long they're going to say, 'Don't mess with that stuff;
that's no good."'

Alternative In Appalachia

Purdue spokesman Jim Heins said the drug could become an alternative to
their top-selling painkiller in areas like rural Appalachia where
prescription drug abuse is especially high.

OxyContin is a slow-release narcotic painkiller that is widely prescribed
for victims of moderate to severe chronic pain resulting from such problems
as arthritis, back trouble and cancer. One pill is designed to last 12
hours, but abusers usually crush the medicine and then snort or inject it,
producing a quick, heroin-like high.

The drug has been blamed for contributing to more than 100 deaths
nationwide. Purdue, which has become the target of at least 13
OxyContin-related lawsuits in five states, says those estimates are
unreliable and that in the vast majority of those cases, the victims were
abusing other drugs at the same time.

Like OxyContin, which was introduced in December 1995, the new drug would
be for victims of moderate to severe chronic pain.

However, it would be embedded with microscopic "beads" of naltrexone, a
narcotic antagonist that counteracts the medicine.

The beads would be coated with a chemical to keep them from dissolving, so
the pain medication will work just like OxyContin if taken properly.

But if the pill is crushed or chopped up, the coating on the beads would
break, releasing the naltrexone and canceling the drug's effects, Haddox said.

Purdue is still conducting tests on the new drug, which could be ready in
three years. Officials have not decided yet whether to make oxycodone the
active ingredient, or to include a different narcotic altogether, like
morphine.

Waiting On FDA

If the Food and Drug Administration approves the drug, it would be one of
only a few abuse-resistant drugs on the market. The first smart pill, a
painkiller called Talwin NX, uses an antagonist called naloxone to achieve
similar effects.

Purdue has been criticized for not reformulating OxyContin to be like
Talwin. Company officials decided against doing so, Haddox said, because
they were concerned that naloxone might create a "ceiling" effect in
OxyContin. Such a drug would not increase in potency past a certain point,
even if a patient takes higher and higher doses.

"We think this is a much more elegant solution to the problem," Haddox said.